|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Early Phase I Study of the Pharmacokinetics and Pharmacodynamics of ABT-888 in Patients With Refractory Solid Tumors or Lymphoid Malignancies
Alternate Title ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Objectives Primary
Secondary
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy:
Patient Characteristics:
Expected Enrollment 23A total of 23 patients will be accrued for this study. Outcomes Primary Outcome(s)Change in tumor poly (ADP-ribose) (PAR) levels from baseline to 3-6 hours after ABT-888 administration Safety of administering 1 dose of ABT-888 Outline This is a dose-finding study. Patients receive oral ABT-888 once on day 1. Cohorts of 3 patients receive escalating doses of ABT-888 until significant tumor poly (ADP-ribose) polymerase (PARP) inhibition is observed in 3 of 3 patients at 2 dose levels. Significant PARP inhibition is defined as ≥ 0.69 reduction on the log scale in poly (ADP-ribose) level from baseline to 3-6 hours after ABT-888 administration (with 90% confidence that it is not due to chance variation). Patients undergo peripheral blood collection at baseline and periodically after ABT-888 administration for PARP inhibition, pharmacokinetic, and pharmacodynamic studies. Once significant PARP inhibition is observed in 1 of 3 patients, subsequently enrolled patients also undergo tumor biopsy* at baseline and 3-6 hours or 21-27 hours after ABT-888 administration to determine PARP inhibition in tumor tissue. [Note: *Patients with chronic lymphocytic leukemia undergo peripheral blood collection instead of biopsy.] After completion of ABT-888 administration, patients are followed for 7 days. Published ResultsKummar S, Kinders R, Gutierrez M, et al.: Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: results of a phase 0 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-3518, 2007. Trial Lead Organizations NCI - Center for Cancer Research
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |